SBRT plus immunotherapy for locally advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining a type of precision radiation (SBRT) with an immunotherapy drug (zimberelimab) for patients with locally advanced pancreatic cancer that cannot be removed by surgery. It aims to see if this combination helps shrink the tumor or control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have locally advanced pancreatic cancer that cannot be surgically removed, and you have not had prior immunotherapy like anti-PD-1 or anti-PD-L1.
- Your overall health is good (ECOG score 0-2), meaning you can take care of yourself and are up and about.
- You have at least one tumor that can be measured on scans.
- You do not have a history of other cancers (except cured skin cancers) or tumor invasion into your stomach or intestines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of radiation therapy (SBRT), two immunotherapy drugs (Ipilimumab and Sintilimab), and two chemotherapy drugs (Nab-Paclitaxel and Gemcitabine) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this treatment can control the cancer better than standard options.
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.